Browsing Tag
Meerkat
2 posts
Roche’s vamikibart sustains vision gains for 52 weeks as July 2027 FDA decision approaches
Genentech has reported sustained visual improvements and reduced retinal swelling through one year in two Phase III studies of vamikibart for uveitic macular edema. Approximately two-thirds of eligible patients required no retreatment after week 16, strengthening the potential treatment's durability profile. However, mixed statistical results between the pivotal trials and the absence of a direct steroid comparison remain important considerations ahead of the expected July 2027 FDA decision.
Hawk Resources (ASX:HWK) has copper drilling momentum, but Cactus now has to prove scale
Hawk Resources has fresh Cactus copper assays and a Q3 drilling catalyst. The test is whether ASX:HWK can turn one strong hole into scale.